Search
What are you looking for?
Start main content

Press Releases

Press Releases

https://www.med.cuhk.edu.hk/press-releases/cuhk-study-proves-ablative-chemoembolization-doubles-the-progression-free-survival-for-liver-cancer-patients
https://www.med.cuhk.edu.hk/press-releases/cuhk-study-proves-ablative-chemoembolization-doubles-the-progression-free-survival-for-liver-cancer-patients

CUHK Study Proves Ablative Chemoembolization Doubles the Progression-Free Survival for Liver Cancer Patients

A study conducted by a multidisciplinary team of the Faculty of Medicine at The Chinese University of Hong Kong (CUHK) has proved that a new transarterial treatment named “Ablative Chemoembolization” (ACE) could prolong the progression-free survival of liver cancer patients at the intermediate stage by twice the length of time, compared with “conventional transarterial chemoembolization” (cTACE). The new treatment is more effective in killing tumour cells of live cancer patients and hence some of them could receive hepatectomy after assessment of their liver conditions, with the aim of curing the disease. The study results have been published in the medical journal Radiology.

 

CUHK Medicine’s Multidisciplinary Team Provides Patient-Centred Treatment for Liver Cancer

Liver cancer is the fifth most common cancer and ranked third in terms of mortality in Hong Kong. According to the Hong Kong Cancer Registry of the Hospital Authority, there were around 1,800 new liver cancer cases locally in 2015 while the number of deaths were around 1,600.

 

As there is a serious impact from liver cancer both locally and internationally, the Faculty of Medicine at CUHK formed a multidisciplinary team to treat this common type of cancer. Experts from the Departments of Oncology, Surgery and Imaging and Interventional Radiology provide multidisciplinary consultation to patients and decide the suitable treatment option for them based on their conditions and surgical risk.

 

Prof. Winnie YEO, Professor of the Department of Clinical Oncology at the Faculty of Medicine at CUHK, stated, “Treatment options available to patients usually depend on their conditions when they are diagnosed with liver cancer. Size, position and metastasis of the tumour, as well as patients’ liver function, are the key factors in determining which treatment protocol is suitable for an individual patient. We hope that through the multidisciplinary consultation provided by specialists in these three Departments, procedures could be optimised and patients could receive comprehensive and patient-centred care as soon as possible.”

 

Hepatectomy not suitable for patients at intermediate stage and new treatment is needed

In general, liver cancer patients at early stage are treated with liver resection, local ablation or liver transplantation. These treatments are applicable to around 30% of all patients only. Patients at the intermediate stage or with high surgical risk are not suitable for liver resection or local ablation, but can only undergo transarterial treatment. For those at terminal stage, chemotherapy and targeted therapy are their only choices.

 

Dr. Kit Fai LEE, Clinical Associate Professor (honorary) of the Department of Surgery at the Faculty of Medicine at CUHK, explained, “Both surgery and local ablation are radical treatments. But if the tumour is too advanced, the tumour has metastasized or liver function has been severely impaired, these treatments will not be available and transarterial treatment will be the only option.”

 

Some patients could receive hepatectomy after the new transarterial treatment

cTACE is a common form of transarterial treatment for liver cancer patients at the intermediate stage. This conventional treatment produces therapeutic effects by causing vascular embolisation in the liver and delivering chemotherapy drugs to cancer cells through catheter. Although other forms of transarterial treatment have been introduced in recent years, such as drug-eluting beads (DEB-TACE) and selective internal radiation (SIRT), these treatments have not been shown to be more effective than cTACE.  

 

Prof. Simon YU, Chairman of the Department of Imaging and Interventional Radiology at the Faculty of Medicine at CUHK, pointed out that the outcomes of the three mentioned transarterial treatments could be much improved and thus it is necessary to develop ACE, the new treatment with better outcomes, to help the liver cancer patients at the intermediate stage. Prof. YU said, “The new technique can significantly increase the concentration of chemotherapeutic drugs in liver cancer tissue. Combined with the effect of ethanol ablation and cutting off the blood supply of liver cancer tissue to cause ischemic necrosis, it can achieve multifold antitumour effect and improve the overall treatment outcome.”

 

The current study conducted by the multidisciplinary team proved that ACE could prolong the progression–free survival of patients while some of them could undergo hepatectomy after assessing their liver conditions.ƒ√

 

In the current study, 44 liver cancer patients were divided into 2 groups, in which one group underwent ACE (study group) while the other underwent cTACE (control group). Their treatment outcomes were analysed and tabulated as follows:

 

 Study group
22 patients
Control group
22 patients
Proportion of patients with complete death of tumour cells after treatment100%45.5%
Proportion of patients who received hepatectomy after treatment32%14%
Progression-free survival (median) 28 months10 months

 

ACE treatment is recommended only to liver cancer patients at intermediate stage with five or fewer tumours. The current study is also a phase 1 study that focused on feasibility and treatment safety. Research team will conduct more in-depth studies on ACE.

 

A study conducted by a multidisciplinary team of the Faculty of Medicine at CUHK proved that a new transarterial treatment named “Ablative Chemoembolization” (ACE) could double the progression-free survival of liver cancer patients at the intermediate stage, compared with conventional treatment. ACE is more effective in killing tumour cells of liver cancer patients and some of them could receive hepatectomy, with the aim of curing the disease. From left: Prof. Winnie YEO, Professor of the Department of Clinical Oncology; Prof. Simon YU, Chairman of the Department of Imaging and Interventional Radiology; Dr. Kit Fai LEE, Clinical Associate Professor (honorary) of the Department of Surgery, from the Faculty of Medicine at CUHK.

A study conducted by a multidisciplinary team of the Faculty of Medicine at CUHK proved that a new transarterial treatment named “Ablative Chemoembolization” (ACE) could double the progression-free survival of liver cancer patients at the intermediate stage, compared with conventional treatment. ACE is more effective in killing tumour cells of liver cancer patients and some of them could receive hepatectomy, with the aim of curing the disease. From left: Prof. Winnie YEO, Professor of the Department of Clinical Oncology; Prof. Simon YU, Chairman of the Department of Imaging and Interventional Radiology; Dr. Kit Fai LEE, Clinical Associate Professor (honorary) of the Department of Surgery, from the Faculty of Medicine at CUHK.

 

Mr YEUNG (right) and Mr WONG (left) both received Ablative Chemoembolization four years ago to kill the tumours in their livers. Both of them are in good conditions.

Mr YEUNG (right) and Mr WONG (left) both received Ablative Chemoembolization four years ago to kill the tumours in their livers. Both of them are in good conditions.

Ablative Chemoembolization can deliver concentrated chemotherapeutic drugs to liver cancer tissue through catheter and other devices. Combined with the effect of ethanol ablation and cutting off the blood supply of liver cancer tissue to cause ischemic necrosis, it can achieve multifold antitumour effect and improve the overall treatment outcome.

Ablative Chemoembolization can deliver concentrated chemotherapeutic drugs to liver cancer tissue through catheter and other devices. Combined with the effect of ethanol ablation and cutting off the blood supply of liver cancer tissue to cause ischemic necrosis, it can achieve multifold antitumour effect and improve the overall treatment outcome.

More Press Releases

CUHK Proves Prostate Artery Embolization Effective for Benign Prostatic Hyperplasia

CUHK Proves Prostate Artery Embolization Effective for Benign Prostatic Hyperplasia

Research
CUHK’s New Prostatic Artery Embolization Shows 90% Success Rate in Relieving Symptoms of Benign Prostatic Hyperplasia

CUHK’s New Prostatic Artery Embolization Shows 90% Success Rate in Relieving Symptoms of Benign Prostatic Hyperplasia

Clinical service
CUHK Succeeded in Animal Study and Clinical Case of Percutaneous Nanoknife New Breakthrough in Cancer Treatment

CUHK Succeeded in Animal Study and Clinical Case of Percutaneous Nanoknife New Breakthrough in Cancer Treatment

Research
CUHK Discovers Innovative ‘Flow Diverters’ (Pipeline) as Effective Treatment for Cerebral Aneurysms in Asia’s First Clinical Study in Collaboration with Seven Medical Centres

CUHK Discovers Innovative ‘Flow Diverters’ (Pipeline) as Effective Treatment for Cerebral Aneurysms in Asia’s First Clinical Study in Collaboration with Seven Medical Centres

Research
CUHK Proves Modified HIFU Treatment Effective for Treating Uterine Fibroids

CUHK Proves Modified HIFU Treatment Effective for Treating Uterine Fibroids

Research
CUHK in collaboration with West China School of Medicine co-Led World’s First-in-human Clinical Trial using CRISPR technology for lung cancer Confirmed gene-edited T-Cell Therapy is Safe and Feasible in Treatment of Advanced NSCLC

CUHK in collaboration with West China School of Medicine co-Led World’s First-in-human Clinical Trial using CRISPR technology for lung cancer Confirmed gene-edited T-Cell Therapy is Safe and Feasible in Treatment of Advanced NSCLC

Research
CUHK to Commence the Next-Generation Clinical Trials of CAR-T Cell Therapy for Haematological Malignancy

CUHK to Commence the Next-Generation Clinical Trials of CAR-T Cell Therapy for Haematological Malignancy

Research
CUHK Successfully Conducts Asia-Pacific’s First Hybrid Operating Room Non-invasive Bronchoscopic Microwave Ablation to Treat Lung Cancer

CUHK Successfully Conducts Asia-Pacific’s First Hybrid Operating Room Non-invasive Bronchoscopic Microwave Ablation to Treat Lung Cancer

Surgical advancement
CUHK Receives an International Cancer Care Team Award Nominated by Patients

CUHK Receives an International Cancer Care Team Award Nominated by Patients

Awards and honors
CUHK-led Global Study Sees Improvement in Overall Survival in Patients with Advanced Lung Cancer

CUHK-led Global Study Sees Improvement in Overall Survival in Patients with Advanced Lung Cancer

Research
CUHK Pioneers Early Lung Cancer Treatment with Hybrid Operating Room Image Guided Electromagnetic Navigation Bronchoscopy

CUHK Pioneers Early Lung Cancer Treatment with Hybrid Operating Room Image Guided Electromagnetic Navigation Bronchoscopy

Surgical advancement
A CUHK-led International Study Demonstrates Immune-checkpoint Inhibitor Is Effective in Patients with Advanced Nasopharyngeal Cancer

A CUHK-led International Study Demonstrates Immune-checkpoint Inhibitor Is Effective in Patients with Advanced Nasopharyngeal Cancer

Research
CUHK-led Research Confirms Novel Targeted Therapy Doubles the Effectiveness of Current Standard Treatment for ALK-Positive Lung Cancer

CUHK-led Research Confirms Novel Targeted Therapy Doubles the Effectiveness of Current Standard Treatment for ALK-Positive Lung Cancer

Research
CUHK Unravels the Whole Genome of Nasopharyngeal Cancer A Great Leap Forward in Personalized Medicine Development

CUHK Unravels the Whole Genome of Nasopharyngeal Cancer A Great Leap Forward in Personalized Medicine Development

Research
Insights into B-cells and GPR18 Gene Expression by CU Medicine team  Improve Prediction of Survival in Multiple Cancer Types

Insights into B-cells and GPR18 Gene Expression by CU Medicine team Improve Prediction of Survival in Multiple Cancer Types

Research
CU Medicine Team Discovers a Novel Prognostic Biomarker for a Doubled Survival in Head and Neck Cancer

CU Medicine Team Discovers a Novel Prognostic Biomarker for a Doubled Survival in Head and Neck Cancer

Research
CUHK Deepening Ties with World Leading Institutes for Transdisciplinary Medical Robotics Research to Reshape the Future of Diagnosis and Treatment

CUHK Deepening Ties with World Leading Institutes for Transdisciplinary Medical Robotics Research to Reshape the Future of Diagnosis and Treatment

International collaboration
CUHK Successfully Conducted the World’s First Multi-Specialty Clinical Trial Using the Next Generation Single Port Robotic Surgical System

CUHK Successfully Conducted the World’s First Multi-Specialty Clinical Trial Using the Next Generation Single Port Robotic Surgical System

Surgical advancement
李嘉誠基金會啟動《愛能助》兒童癌症項目 資助兒童罕見癌症 (Chinese version only)

李嘉誠基金會啟動《愛能助》兒童癌症項目 資助兒童罕見癌症 (Chinese version only)

Donation
Professor Tony MOK Honoured with the ESMO Lifetime Achievement Award Recognising His Global Leadership in Defining Lung Cancer Treatment Standard

Professor Tony MOK Honoured with the ESMO Lifetime Achievement Award Recognising His Global Leadership in Defining Lung Cancer Treatment Standard

Awards and honors
CUHK Launches Multi-Cancer Prevention Programme Providing Free Screening to 10,000 HK Residents to Study Links with Obesity

CUHK Launches Multi-Cancer Prevention Programme Providing Free Screening to 10,000 HK Residents to Study Links with Obesity

Health Campaign
CUHK Study Sees Increasing Global Incidence of Colorectal Cancer Among Younger People

CUHK Study Sees Increasing Global Incidence of Colorectal Cancer Among Younger People

Research
CUHK Discovers an Essential Oncogene in Non-Alcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma

CUHK Discovers an Essential Oncogene in Non-Alcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma

Research
CUHK Research Receives Recognitions by Top Medical Journals

CUHK Research Receives Recognitions by Top Medical Journals

Awards and honors
CUHK-HKU Study on Multi-gene Mutation-Drug Matching for Recurrent Ovarian Cancer Patients Providing Free Pharmacogenomic Analysis for 100 Patients in Hong Kong

CUHK-HKU Study on Multi-gene Mutation-Drug Matching for Recurrent Ovarian Cancer Patients Providing Free Pharmacogenomic Analysis for 100 Patients in Hong Kong

Research
CUHK Study Reveals Patients with Recovery of Hepatitis B Still at Risk of Liver Cancer

CUHK Study Reveals Patients with Recovery of Hepatitis B Still at Risk of Liver Cancer

Research
CUHK Completes a 20,000-person Plasma DNA Screening Study of Nasopharyngeal Cancer, and Finds a Dramatic Shift to Early Stage Cancers

CUHK Completes a 20,000-person Plasma DNA Screening Study of Nasopharyngeal Cancer, and Finds a Dramatic Shift to Early Stage Cancers

Research
CUHK Uncovers Novel Immune Escape Mechanism of Cancer Opening Up New Direction for Cancer Immunotherapy

CUHK Uncovers Novel Immune Escape Mechanism of Cancer Opening Up New Direction for Cancer Immunotherapy

Research
World’s First Large-scale Epidemiological Survey on Adolescents by CUHK Reveals Abuse of Methamphetamine Associated with Increased Risk of Developing Lower Urinary Tract Symptoms

World’s First Large-scale Epidemiological Survey on Adolescents by CUHK Reveals Abuse of Methamphetamine Associated with Increased Risk of Developing Lower Urinary Tract Symptoms

Clinical service
CUHK World’s First Study Confirms A New Colorectal Cancer High Risk Group

CUHK World’s First Study Confirms A New Colorectal Cancer High Risk Group

Research
CUHK Sets up the Global First Research Registry on Early Onset Dementia in Chinese Population

CUHK Sets up the Global First Research Registry on Early Onset Dementia in Chinese Population

Research
CUHK Screening Reveals 1 in 3 Older Adults in Community Suffer Brain Small Vessel Disease, Early Prevention Recommended

CUHK Screening Reveals 1 in 3 Older Adults in Community Suffer Brain Small Vessel Disease, Early Prevention Recommended

Clinical service
CUHK Introduces High Frequency Oscillations to Determine Resection Margin Increases the Effectiveness of Complex Epilepsy Surgery by around 30%

CUHK Introduces High Frequency Oscillations to Determine Resection Margin Increases the Effectiveness of Complex Epilepsy Surgery by around 30%

Surgical advancement
CUHK and PWH Introduce Leading 3D Imaging System which Reduces Radiation Dosage by 90%

CUHK and PWH Introduce Leading 3D Imaging System which Reduces Radiation Dosage by 90%

Clinical service
CUHK Succeeds in Treating Gastroesophageal Reflux Disease by Implantable Pulse Generator

CUHK Succeeds in Treating Gastroesophageal Reflux Disease by Implantable Pulse Generator

Surgical advancement
CUHK Assessed and Treated Over 300 Young Ketamine Abusers with Urinary Tract Dysfunction Latest Research Reveals Effectiveness of Integrated Anti-inflammatory Therapy

CUHK Assessed and Treated Over 300 Young Ketamine Abusers with Urinary Tract Dysfunction Latest Research Reveals Effectiveness of Integrated Anti-inflammatory Therapy

Research
CUHK-HCC Score Accurately Predicts Risk of Liver Cancer in Chronic Hepatitis B Patients Receiving Antiviral Therapy

CUHK-HCC Score Accurately Predicts Risk of Liver Cancer in Chronic Hepatitis B Patients Receiving Antiviral Therapy

Research

Our Expert List

Many experts under the Faculty of Medicine are available for media interview.
Please click here for the expert list or contact us.